

Andrea Knezevic, MS

Department of Epidemiology & Biostatistics
Memorial Sloan Kettering Cancer Center
633 3rd Ave, Floor 3
New York, NY 10017

knezevia@mskcc.org

<https://www.mskcc.org/profile/andrea-knezevic>

EDUCATION

- 2013 **M.S., Statistics**, Georgia Institute of Technology, Atlanta, Georgia
2008 **B.S., Biometry & Statistics**, Cornell University, Ithaca, New York

PROFESSIONAL APPOINTMENTS

- 2020-Present **Research Biostatistician II**, Department of Epidemiology & Biostatistics,
Memorial Sloan Kettering Cancer Center
2017-2020 **Research Biostatistician**, Department of Epidemiology & Biostatistics,
Memorial Sloan Kettering Cancer Center
2013-2017 **Senior Biostatistician**, Department of Biostatistics & Bioinformatics,
Rollins School of Public Health, Emory University
2008-2013 **Data Analyst**, Department of Biostatistics & Bioinformatics, Rollins
School of Public Health, Emory University
2008 **Data Analyst**, Cornell Statistical Consulting Unit, Cornell University

TEACHING

- Summer 2014-2016 **Instructor**, Introduction to Epidemiology & Biostatistics
School of Medicine
Emory University
Fall 2013, 2014 **Instructor**, Statistical Methods I Laboratory
Rollins School of Public Health
Emory University
Spring 2014, 2015 **Instructor**, Statistical Methods II Laboratory
Rollins School of Public Health
Emory University

PROFESSIONAL MEMBERSHIPS

- 2008-Present **Member**, American Statistical Association
2019-Present **Member**, International Biometrics Society-ENAR

PROFESSIONAL SERVICE

INTRAMURAL

- 2021-Present **Chair**, Biostatistics Protocol Review Committee, Memorial Sloan Kettering Cancer Center
- 2020-2022 **Organizer**, Biostatistics Master's Seminar Series, Department of Epidemiology & Biostatistics, Memorial Sloan Kettering Cancer Center
- 2019-2021 **Reviewer**, Biostatistics Protocol Review Committee, Memorial Sloan Kettering Cancer Center

EXTRAMURAL

- 2022-Present **Statistical Reviewer**, Journal of Clinical Oncology
- 2020-Present **Invited Statistical Reviewer**, Journal of the National Cancer Institute
- 2019-Present **Ad hoc Statistical Reviewer**
JAMA Oncology
Nature Medicine
BMC Medical Research Methodology
- 2020 **Invited Panelist**, Careers in Biostatistics and Data Science Panel, New York University

PRESENTATIONS

- Invited Knezevic A, Patil S. (2020). "Methods for estimation and inference of cumulative incidence with missing cause of failure." Presented at the Joint Statistical Meetings, Virtual Conference, Aug 5 2020.

SOFTWARE

GitHub: <https://github.com/dreaknezevic>

- combo-WLR**: SAS macro performs combinations of Fleming-Harrington weighted log-rank tests, useful for survival analysis hypothesis testing in the presence of nonproportional hazards. Includes estimation of the variance-covariance matrix of the joint distribution of the Z-statistics and calculation of the p-value for the maximum test statistic. *Knezevic, Patil (2020), SAS Global Forum*.
- CIF-MI**: SAS macro to generate a cumulative incidence function from competing risks data with missing event type. A two-step approach uses proper multiple imputation for missing event type and subsequent combination of multiple estimates using Rubin's rules to obtain a nonparametric cumulative incidence function estimate. *Knezevic, Patil (2020), Joint Statistical Meetings Conference Proceedings*.

RESEARCH SUPPORT

5 P30 CA008748-57 (PI: Thompson/Gonen) 02/01/2019-12/31/2023
NIH/NCI \$520,671

Cancer Center Support Grant (Biostatistics)

The CCSG funds support MSKCC's research infrastructure. These shared resources facilitate the research activities of the clinical, translational and laboratory programs at the Cancer Center.

Role: Research Biostatistician

- AWD00000799 (PI: Desai) 07/01/2021-06/30/2023
 National Palliative Care Research Center \$180,000
 Values Added:” Utilization and Effect of a “Patient Values Tab” in the Electronic Health Record
 Research Aim 1: Elicit perspectives of Black and Latinx cancer patients on the relevance, acceptability, and importance of Tab content as a composite of information to promote person centered care. Research Aim 2: Examine oncologist adoption of the Tab to identify patterns as well as barriers and facilitators for broad and equitable implementation in clinical care. Research Aim 3: Evaluate impact of Tab adoption by oncologists on perceptions of person centeredness of care as reported by Black, Latinx, and other patients with cancer, and by their oncologists.
 Role: Research Biostatistician
- 5 R01 CA233885-03 (PI: Barnes) 08/01/2019-07/31/2024
 NIH/NCI \$145,168
 Association between body composition and treatment-related outcomes among metastatic kidney cancer patients treated with immunotherapy
 Our study will improve the measurement of BMI by calculating exactly how much muscle and fat a kidney cancer patient has and determining for the first time how those tissues relate to tumor aggressiveness and to survival.
 Role: Research Biostatistician
- GC239266 (PI: Robson) 06/30/2019 - 06/29/2022
 Breast Cancer Research Foundation \$480,144
 Development of a TNBC Risk Score incorporating polygenic risk and radiomic features defined through digital image-coupled machine learning
 We have assembled a multidisciplinary team of breast radiologists, breast surgeons, medical oncologists, clinical cancer geneticists, medical physicists, data scientists, and statisticians to attack this problem in a novel way, combining new methodologies such as advanced imaging-coupled ML with traditional risk-assessment tools.
 Role: Biostatistician
- 5 P30 AI050409-17 (PI: Del Rio) 09/30/12-07/31/17
 NIH/NIAID \$3,327,667
 Emory/Atlanta Center for Aids Research (CFAR)
 The primary goal of the CFAR Biostatistics Core is to strengthen the statistical science and rigor of HIV/AIDS-related research.
 Role: Senior Biostatistician
- 5 P01 HL086773-07 (PI: Roback) 07/01/15-02/01/17
 NIH/NHLBI \$1,669,016
 Serious Hazards of Transfusion and Cellular Therapies: Mechanisms and Interventions
 The primary goal is to address mechanisms and mitigate the effects of several of the most serious causes of morbidity and mortality in transfusion medicine.
 Role: Senior Biostatistician
- 5 U19 AI111211-02 (PI: Blumberg) 08/11/14-02/01/17
 NIH/NIAID \$2,910,650
 Role of Antigen Specific T Cell Responses in the Control of TB
 Our TBRU focuses on immunity to M. tuberculosis (Mtb), to test the overall hypothesis that latent TB

infection (LTBI) exists as a spectrum of bacterial and immunologic states, that at least three immunological states can be distinguished and correspond to: 1) past but cleared Mtb infection; 2] stable LTBI with a low risk of progression to active disease; or 3) LTBI with a high risk of progression to active TB disease.

Role: Senior Biostatistician

1 K23 HL128942-01A1 (PI: Patel) 05/01/16-02/01/17

NIH/NHLBI \$166,212

Red Cell Transfusion, Severe Anemia and Necrotizing Enterocolitis

This proposal will capitalize on the unique opportunity provided by recently collected data from a completed prospective, multicenter birth cohort study and an upcoming prospective study.

Role: Senior Biostatistician

1 P01 HL086773-01A1 (PI: Hillyer) 09/15/08-08/31/13

NIH \$1,874,127

Mechanisms and Interventions Addressing Serious Hazards of Transfusion and Cellular Therapies

The primary goal is to address mechanisms of, and mitigate the effects of several of the most serious causes of morbidity and mortality in transfusion medicine.

Role: Data Analyst

1R01AR059364-01 (PI: Weitzmann) 12/01/09-11/30/14

NIH

Effect of HIV-Infection and HAART on Bone Homestasis

The purpose of these studies is to elucidate mechanisms underlying age-induced osteoporosis in HIV-infected patients initiating HAART

Role: Data Analyst

BIBLIOGRAPHY

Orcid: <https://orcid.org/0000-0002-0741-2150>

PubMed: <https://www.ncbi.nlm.nih.gov/myncbi/1jCptzhe7p4QPp/bibliography/public/>

Google Scholar: <https://scholar.google.com/citations?user=N6BqUOcAAAAJ>

ARTICLES IN PEER-REVIEWED JOURNALS

1. Kotecha RR, Doshi SD, Knezevic A, Chaim J, Chen Y, Jacobi R, Zucker M, Reznik E, McHugh D, Shah NJ, Feld E, Aggen DH, Rafelson W, Xiao H, Carlo MI, Feldman DR, Lee CH, Motzer RJ, Voss MH. A Phase 2 Trial of Talazoparib and Avelumab in Genomically Defined Metastatic Kidney Cancer. *Eur Urol Oncol*. 2024 Aug;7(4):804-811. doi: 10.1016/j.euo.2023.10.017. Epub 2023 Nov 7. PubMed PMID: 37945488; PubMed Central PMCID: PMC11074239.
2. Bradshaw PT, Olsson LT, Sanchez A, Knezevic A, Akin O, Scott JM, Hakimi AA, Russo P, Caan BJ, Mourtzakis M, Furberg H. Radiodensities of skeletal muscle and visceral adipose tissues are prognostic factors in clear cell renal cell carcinoma. *Cancer Epidemiol Biomarkers Prev*. 2024 Jul 29;. doi: 10.1158/1055-9965.EPI-24-0306. PubMed PMID: 39073365.
3. Gleeson JP, Knezevic A, Bromberg M, Patil S, Sheinfeld J, Carver BS, Bains M, Jones DR, Bajorin DF, Bosl GJ, McHugh DJ, Funt SA, Motzer RJ, Feldman DR. Paclitaxel, Ifosfamide, and Cisplatin as Initial Salvage Chemotherapy for Germ Cell Tumors: Long-Term Follow-Up and Outcomes for Favorable- and Unfavorable-Risk Disease. *J Clin Oncol*. 2024 Jul 19;.JCO2302542. doi: 10.1200/JCO.23.02542. PubMed PMID: 39028926.
4. Gutgarts V, Gerardine S, Shingarev RA, Knezevic A, Zabor EC, Latcha S, Joy MS, Aleksunes LM, Jaimes EA. Evaluation of Cisplatin-Induced Acute Kidney Injury in Patients Co-Prescribed Serotonin

- Receptor Antagonists: A Retrospective Analysis. *Kidney360*. 2024 May 30;. doi: 10.34067/KID.0000000000000464. PubMed PMID: 38814726.
5. Fitzgerald KN, Lee CH, Voss MH, Carlo MI, Knezevic A, Peralta L, Chen Y, Lefkowitz RA, Shah NJ, Owens CN, McHugh DJ, Aggen DH, Laccetti AL, Kotecha RR, Feldman DR, Motzer RJ. Cabozantinib Plus Nivolumab in Patients with Non-Clear Cell Renal Cell Carcinoma: Updated Results from a Phase 2 Trial. *Eur Urol*. 2024 May 22;. doi: 10.1016/j.eururo.2024.04.025. PubMed PMID: 38782695.
 6. Furberg H, Bradshaw PT, Knezevic A, Olsson L, Petruzella S, Stein E, Paris M, Scott J, Akin O, Hakimi AA, Russo P, Sanchez A, Caan B, Mourtzakis M. Skeletal muscle and visceral adipose radiodensities are pre-surgical, non-invasive markers of aggressive kidney cancer. *J Cachexia Sarcopenia Muscle*. 2024 Apr;15(2):726-734. doi: 10.1002/jcsm.13429. Epub 2024 Jan 24. PubMed PMID: 38263932; PubMed Central PMCID: PMC10995262.
 7. Kotecha RR, Knezevic A, Arora K, Bandlamudi C, Kuo F, Carlo MI, Fitzgerald KN, Feldman DR, Shah NJ, Reznik E, Hakimi AA, Carrot-Zhang J, Mandelker D, Berger M, Lee CH, Motzer RJ, Voss MH. Genomic ancestry in kidney cancer: Correlations with clinical and molecular features. *Cancer*. 2024 Mar 1;130(5):692-701. doi: 10.1002/cncr.35074. Epub 2023 Oct 21. PubMed PMID: 37864521.
 8. Blum KA, Silagy AW, Knezevic A, Weng S, Wang A, Mano R, Marcon J, DiNatale RG, Sanchez A, Tickoo S, Gupta S, Motzer R, Haas NB, Kim SE, Uzzo RG, Coleman JA, Hakimi AA, Russo P. Localised non-metastatic sarcomatoid renal cell carcinoma: a 31-year externally verified study. *BJU Int*. 2024 Feb;133(2):169-178. doi: 10.1111/bju.16125. Epub 2023 Sep 9. PubMed PMID: 37589200; PubMed Central PMCID: PMC10841268.
 9. Matulewicz RS, Benfante N, Funt SA, Feldman DR, Carver B, Doudt A, Knezevic A, Sheinfeld J. Primary Retroperitoneal Lymph Node Dissection for Seminoma Metastatic to the Retroperitoneum. *J Urol*. 2024 Jan;211(1):80-89. doi: 10.1097/JU.0000000000003697. Epub 2023 Sep 6. PubMed PMID: 37672753.
 10. Funt SA, Knezevic A, Wilson K, Bromberg M, Budnick A, O'Connor KL, McHugh DJ, Larsen E, Bajorin DF, Motzer RJ, Tonorezos ES, Patil S, Feldman DR. Ototoxicity associated with high-dose carboplatin for patients with previously treated germ cell tumors. *Cancer*. 2023 Dec 15;129(24):3952-3961. doi: 10.1002/cncr.34991. Epub 2023 Sep 16. PubMed PMID: 37715631.
 11. Epstein AS, Knezevic A, Romano DR, Hoque A, Raj N, Reidy D, Rosa WE, Cruz E, Calderon C, O'Shaughnessy S, Sansone A, Okpako M, Nelson JE. Patient Portals to Elicit Essential Patient-Reported Elements of Communication Supporting Person-Centered Oncologic Care: A Pilot Study of the PERSON Approach. *JCO Clin Cancer Inform*. 2023 Sep;7:e2300125. doi: 10.1200/CCI.23.00125. PubMed PMID: 37890120; PubMed Central PMCID: PMC10642868.
 12. Fitzgerald KN, Duzgol C, Knezevic A, Shapnik N, Kotecha R, Aggen DH, Carlo MI, Shah NJ, Voss MH, Feldman DR, Motzer RJ, Lee CH. Progression-free Survival After Second Line of Therapy for Metastatic Clear Cell Renal Cell Carcinoma in Patients Treated with First-line Immunotherapy Combinations. *Eur Urol*. 2023 Mar;83(3):195-199. doi: 10.1016/j.eururo.2022.10.017. Epub 2022 Nov 4. PubMed PMID: 36344318; PubMed Central PMCID: PMC10599591.
 13. Liu YL, Manning-Geist BL, Knezevic A, Deng L, Bromberg M, Funt SA, Meisel JL, Zivanovic O, Roche KL, Sonoda Y, Gardner GJ, Grisham RN, O'Cearbhaill RE, Tew WP, Abu-Rustum NR, Chi DS, Aghajanian C, Feldman DR. Predicting outcomes in female germ cell tumors using a modified International Germ Cell Cancer Collaborative Group classification system to guide management. *Gynecol Oncol*. 2023 Mar;170:93-101. doi: 10.1016/j.ygyno.2022.12.022. Epub 2023 Jan 18. PubMed PMID: 36669327; PubMed Central PMCID: PMC10023473.

14. Agarwal R, Shin P, Knezevic A, Nelson JE, Romano DR, Bernal C, Desai AV, Epstein AS. Accuracy of curability expectations in patients with gastrointestinal cancers. *Cancer Med.* 2023 Jan;12(1):20-29. doi: 10.1002/cam4.4947. Epub 2022 Jun 15. PubMed PMID: 35959986; PubMed Central PMCID: PMC9844646.
15. Ged Y, Sanchez A, Patil S, Knezevic A, Stein E, Petruzella S, Weiss K, Duzgol C, Chaim J, Akin O, Mourtzakis M, Paris MT, Scott J, Kuo F, Kotecha R, Hakimi AA, Lee CH, Motzer RJ, Voss MH, Furberg H. Associations between Pretreatment Body Composition Features and Clinical Outcomes among Patients with Metastatic Clear Cell Renal Cell Carcinoma Treated with Immune Checkpoint Blockade. *Clin Cancer Res.* 2022 Dec 1;28(23):5180-5189. doi: 10.1158/1078-0432.CCR-22-1389. PubMed PMID: 36190538; PubMed Central PMCID: PMC9793646.
16. Scordo M, Shah GL, Adintori PA, Knezevic A, Devlin SM, Buchan ML, Preston EV, Lin AP, Rodriguez NT, Carino CA, Nguyen LK, Sitner NC, Barasch A, Klang MG, Maloy MA, Mastrogiacomo B, Carlow DC, Schofield RC, Slingerland AE, Slingerland JB, Stein-Thoeringer CK, Lahoud OB, Landau HJ, Chung DJ, van den Brink MRM, Peled JU, Giralta SA. A prospective study of dysgeusia and related symptoms in patients with multiple myeloma after autologous hematopoietic cell transplantation. *Cancer.* 2022 Nov 1;128(21):3850-3859. doi: 10.1002/ncr.34444. Epub 2022 Aug 30. PubMed PMID: 36041227; PubMed Central PMCID: PMC10010839.
17. Kuehn D, Zeisel SH, Orenstein DF, German JB, Field CJ, Teerdhala S, Knezevic A, Patil S, Donovan SM, Lönnerdal B. Effects of a Novel High-Quality Protein Infant Formula on Energetic Efficiency and Tolerance: A Randomized Trial. *J Pediatr Gastroenterol Nutr.* 2022 Oct 1;75(4):521-528. doi: 10.1097/MPG.0000000000003490. Epub 2022 Jun 6. PubMed PMID: 35666855; PubMed Central PMCID: PMC9470040.
18. Erazo T, Evans CM, Zakheim D, Chu KL, Refermat AY, Asgari Z, Yang X, Da Silva Ferreira M, Mehta S, Russo MV, Knezevic A, Zhang XP, Chen Z, Fennell M, Garippa R, Seshan V, de Stanchina E, Barbash O, Batlevi CL, Leslie CS, Melnick AM, Younes A, Kharas MG. TP53 mutations and RNA-binding protein MUSASHI-2 drive resistance to PRMT5-targeted therapy in B-cell lymphoma. *Nat Commun.* 2022 Sep 27;13(1):5676. doi: 10.1038/s41467-022-33137-8. PubMed PMID: 36167829; PubMed Central PMCID: PMC9515221.
19. Lee CH, Voss MH, Carlo MI, Chen YB, Zucker M, Knezevic A, Lefkowitz RA, Shapnik N, Dadoun C, Reznik E, Shah NJ, Owens CN, McHugh DJ, Aggen DH, Laccetti AL, Kotecha R, Feldman DR, Motzer RJ. Phase II Trial of Cabozantinib Plus Nivolumab in Patients With Non-Clear-Cell Renal Cell Carcinoma and Genomic Correlates. *J Clin Oncol.* 2022 Jul 20;40(21):2333-2341. doi: 10.1200/JCO.21.01944. Epub 2022 Mar 17. PubMed PMID: 35298296; PubMed Central PMCID: PMC9287282.
20. Kotecha RR, Gedvilaite E, Ptashkin R, Knezevic A, Murray S, Johnson I, Shapnik N, Feldman DR, Carlo MI, Shah NJ, Dunigan M, Huberman K, Benayed R, Zehir A, Berger MF, Ladanyi M, Tsui DWY, Motzer RJ, Lee CH, Voss MH. Matched Molecular Profiling of Cell-Free DNA and Tumor Tissue in Patients With Advanced Clear Cell Renal Cell Carcinoma. *JCO Precis Oncol.* 2022 Jul;6:e2200012. doi: 10.1200/PO.22.00012. PubMed PMID: 35797508; PubMed Central PMCID: PMC9489165.
21. Smith AGC, Kempker RR, Wassie L, Bobosha K, Nizam A, Gandhi NR, Auld SC, Magee MJ, Blumberg HM. The Impact of Diabetes and Prediabetes on Prevalence of Mycobacterium tuberculosis Infection Among Household Contacts of Active Tuberculosis Cases in Ethiopia. *Open Forum Infect Dis.* 2022 Jul;9(7):ofac323. doi: 10.1093/ofid/ofac323. eCollection 2022 Jul. PubMed PMID: 36420425; PubMed Central PMCID: PMC9595051.

22. Golia Pernicka JS, Bates DDB, Fuqua JL 3rd, Knezevic A, Yoon J, Nardo L, Petkovska I, Paroder V, Nash GM, Markowitz AJ, Gollub MJ. Meaningful words in rectal MRI synoptic reports: How "polypoid" may be prognostic. *Clin Imaging*. 2021 Dec;80:371-376. doi: 10.1016/j.clinimag.2021.08.010. Epub 2021 Aug 26. PubMed PMID: 34517303; PubMed Central PMCID: PMC8585689.
23. Portelinha A, Thompson S, Smith RA, Da Silva Ferreira M, Asgari Z, Knezevic A, Seshan V, de Stanchina E, Gupta S, Denis L, Younes A, Reddy S. ASN007 is a *in vivo* ERK1/2 inhibitor with preferential activity against RAS-and RAF-mutant tumors. *Cell Rep Med*. 2021 Jul 20;2(7):100350. doi: 10.1016/j.xcrm.2021.100350. eCollection 2021 Jul 20. PubMed PMID: 34337566; PubMed Central PMCID: PMC8324497.
24. Funt SA, McHugh DJ, Tsai S, Knezevic A, O'Donnell D, Patil S, Silber D, Bromberg M, Carousso M, Reuter VE, Carver BS, Sheinfeld J, Motzer RJ, Bajorin DF, Bosl GJ, Feldman DR. Four Cycles of Etoposide plus Cisplatin for Patients with Good-Risk Advanced Germ Cell Tumors. *Oncologist*. 2021 Jun;26(6):483-491. doi: 10.1002/onco.13719. Epub 2021 Mar 12. PubMed PMID: 33586274; PubMed Central PMCID: PMC8176973.
25. Espinoza TR, Hendershot KA, Liu B, Knezevic A, Jacobs BB, Gore RK, Guskiewicz KM, Bazarian JJ, Phelps SE, Wright DW, LaPlaca MC. A Novel Neuropsychological Tool for Immersive Assessment of Concussion and Correlation with Subclinical Head Impacts. *Neurotrauma Rep*. 2021;2(1):232-244. doi: 10.1089/neur.2020.0022. eCollection 2021. PubMed PMID: 34223554; PubMed Central PMCID: PMC8240822.
26. Gleeson JP, Nikolovski I, Dinatale R, Zucker M, Knezevic A, Patil S, Ged Y, Kotecha RR, Shapnik N, Murray S, Russo P, Coleman J, Lee CH, Stadler ZK, Hakimi AA, Feldman DR, Motzer RJ, Reznik E, Voss MH, Chen YB, Carlo MI. Comprehensive Molecular Characterization and Response to Therapy in Fumarate Hydratase-Deficient Renal Cell Carcinoma. *Clin Cancer Res*. 2021 May 15;27(10):2910-2919. doi: 10.1158/1078-0432.CCR-20-4367. Epub 2021 Mar 3. PubMed PMID: 33658299; PubMed Central PMCID: PMC8127353.
27. Arbour KC, Rizvi H, Plodkowski AJ, Hellmann MD, Knezevic A, Heller G, Yu HA, Ladanyi M, Kris MG, Arcila ME, Rudin CM, Lito P, Riely GJ. Treatment Outcomes and Clinical Characteristics of Patients with KRAS-G12C-Mutant Non-Small Cell Lung Cancer. *Clin Cancer Res*. 2021 Apr 15;27(8):2209-2215. doi: 10.1158/1078-0432.CCR-20-4023. Epub 2021 Feb 8. PubMed PMID: 33558425; PubMed Central PMCID: PMC8771577.
28. Feldman DR, Ged Y, Lee CH, Knezevic A, Molina AM, Chen YB, Chaim J, Coskey DT, Murray S, Tickoo SK, Reuter VE, Patil S, Xiao H, Aghalar J, Apollo AJ, Carlo MI, Motzer RJ, Voss MH. Everolimus plus bevacizumab is an effective first-line treatment for patients with advanced papillary variant renal cell carcinoma: Final results from a phase II trial. *Cancer*. 2020 Dec 15;126(24):5247-5255. doi: 10.1002/ncr.33148. Epub 2020 Sep 25. PubMed PMID: 32975815; PubMed Central PMCID: PMC8366407.
29. Pawloski KR, Christian N, Knezevic A, Wen HY, Van Zee KJ, Morrow M, Tadros AB. Atypical ductal hyperplasia bordering on DCIS on core biopsy is associated with higher risk of upgrade than conventional atypical ductal hyperplasia. *Breast Cancer Res Treat*. 2020 Dec;184(3):873-880. doi: 10.1007/s10549-020-05890-1. Epub 2020 Aug 28. PubMed PMID: 32857242; PubMed Central PMCID: PMC7657999.
30. Montagna G, Mamtani A, Knezevic A, Brogi E, Barrio AV, Morrow M. ing Node-Positive Patients for Axillary Downstaging with Neoadjuvant Chemotherapy. *Ann Surg Oncol*. 2020 Oct;27(11):4515-4522.

doi: 10.1245/s10434-020-08650-z. Epub 2020 Jun 2. PubMed PMID: 32488513; PubMed Central PMCID: PMC7501229.

31. Jain T, Knezevic A, Pennisi M, Chen Y, Ruiz JD, Purdon TJ, Devlin SM, Smith M, Shah GL, Halton E, Diamonte C, Scordo M, Sauter CS, Mead E, Santomasso BD, Palomba ML, Batlevi CW, Maloy MA, Giralt S, Smith E, Brentjens R, Park JH, Perales MA, Mailankody S. Hematopoietic recovery in patients receiving chimeric antigen receptor T-cell therapy for hematologic malignancies. *Blood Adv.* 2020 Aug 11;4(15):3776-3787. doi: 10.1182/bloodadvances.2020002509. PubMed PMID: 32780846; PubMed Central PMCID: PMC7422135.
32. Ged Y, Gupta R, Duzgol C, Knezevic A, Shapnik N, Kotecha R, Voss MH, Feldman DR, Akin O, Patil S, Motzer RJ, Rini BI, Lee CH. Systemic therapy for advanced clear cell renal cell carcinoma after discontinuation of immune-oncology and VEGF targeted therapy combinations. *BMC Urol.* 2020 Jul 2;20(1):84. doi: 10.1186/s12894-020-00647-w. PubMed PMID: 32616076; PubMed Central PMCID: PMC7331268.
33. Ged Y, Chaim JL, DiNatale RG, Knezevic A, Kotecha RR, Carlo MI, Lee CH, Foster A, Feldman DR, Teo MY, Iyer G, Chan T, Patil S, Motzer RJ, Hakimi AA, Voss MH. DNA damage repair pathway alterations in metastatic clear cell renal cell carcinoma and implications on systemic therapy. *J Immunother Cancer.* 2020 Jun;8(1). doi: 10.1136/jitc-2019-000230. PubMed PMID: 32571992; PubMed Central PMCID: PMC7311069.
34. McHugh DJ, Funt SA, Silber D, Knezevic A, Patil S, O'Donnell D, Tsai S, Reuter VE, Sheinfeld J, Carver BS, Motzer RJ, Bajorin DF, Bosl GJ, Feldman DR. Adjuvant Chemotherapy With Etoposide Plus Cisplatin for Patients With Pathologic Stage II Nonseminomatous Germ Cell Tumors. *J Clin Oncol.* 2020 Apr 20;38(12):1332-1337. doi: 10.1200/JCO.19.02712. Epub 2020 Feb 28. PubMed PMID: 32109195; PubMed Central PMCID: PMC7164484.
35. Carlo MI, Ravichandran V, Srinivasan P, Bandlamudi C, Kemel Y, Ceyhan-Birsoy O, Mukherjee S, Mandelker D, Chaim J, Knezevic A, Rana S, Fnu Z, Breen K, Arnold AG, Khurram A, Tkachuk K, Cipolla CK, Regazzi A, Hakimi AA, Al-Ahmadie H, Dalbagni G, Cadoo KA, Walsh MF, Teo MY, Funt SA, Coleman JA, Bochner BH, Iyer G, Solit DB, Stadler ZK, Zhang L, Rosenberg JE, Taylor BS, Robson ME, Berger MF, Vijai J, Bajorin DF, Offit K. Cancer Susceptibility Mutations in Patients With Urothelial Malignancies. *J Clin Oncol.* 2020 Feb 10;38(5):406-414. doi: 10.1200/JCO.19.01395. Epub 2019 Dec 3. PubMed PMID: 31794323; PubMed Central PMCID: PMC7351337.
36. Patel MA, Kollmeier M, McBride S, Gorovets D, Varghese M, Chan L, Knezevic A, Zhang Z, Zelefsky MJ. Early biochemical predictors of survival in intermediate and high-risk prostate cancer treated with radiation and androgen deprivation therapy. *Radiother Oncol.* 2019 Nov;140:34-40. doi: 10.1016/j.radonc.2019.04.003. Epub 2019 Jun 6. PubMed PMID: 31177042; PubMed Central PMCID: PMC7542885.
37. Kondraciuk JD, Rice SL, Zhou X, Gharzeddine K, Knezevic A, Spratt DE, Sabra M, Larson SM, Grewal RK, Osborne JR. Thyroid Cancer Bone Metastasis: Survival and Genomic Characteristics of a Large Tertiary Care Cohort. *Clin Nucl Med.* 2019 Aug;44(8):e465-e471. doi: 10.1097/RLU.0000000000002626. PubMed PMID: 31274625; PubMed Central PMCID: PMC6621602.
38. Ged Y, Chen YB, Knezevic A, Donoghue MTA, Carlo MI, Lee CH, Feldman DR, Patil S, Hakimi AA, Russo P, Voss MH, Motzer RJ. Mucinous Tubular and Spindle-Cell Carcinoma of the Kidney: Clinical Features, Genomic Profiles, and Treatment Outcomes. *Clin Genitourin Cancer.* 2019 Aug;17(4):268-274.e1. doi: 10.1016/j.clgc.2019.04.006. Epub 2019 May 2. PubMed PMID: 31151928; PubMed Central PMCID: PMC6660413.

39. Patel RM, Shenvi N, Knezevic A, Hinkes M, Bugg GW, Stowell SR, Roback JD, Easley KA, Josephson C. Observational study of cytomegalovirus from breast milk and necrotising enterocolitis. *Arch Dis Child Fetal Neonatal Ed.* 2019 Jul 20;105(3):259-65. doi: 10.1136/archdischild-2018-316613. [Epub ahead of print] PubMed PMID: 31326920; PubMed Central PMCID: PMC7336338.
40. Osborne JR, Kondraciuk JD, Rice SL, Zhou X, Knezevic A, Spratt DE, Sabra M, Larson SM, Grewal RK. Thyroid Cancer Brain Metastasis: Survival and Genomic Characteristics of a Large Tertiary Care Cohort. *Clin Nucl Med.* 2019 Jul;44(7):544-549. doi: 10.1097/RLU.0000000000002618. PubMed PMID: 31107749; PubMed Central PMCID: PMC6546545.
41. Ged Y, Chen YB, Knezevic A, Casuscelli J, Redzematovic A, DiNatale RG, Carlo MI, Lee CH, Feldman DR, Patil S, Hakimi AA, Russo P, Motzer RJ, Voss MH. Metastatic Chromophobe Renal Cell Carcinoma: Presence or Absence of Sarcomatoid Differentiation Determines Clinical Course and Treatment Outcomes. *Clin Genitourin Cancer.* 2019 Jun;17(3):e678-e688. doi: 10.1016/j.clgc.2019.03.018. Epub 2019 Apr 1. PubMed PMID: 31036466; PubMed Central PMCID: PMC6752712.
42. Patel RM, Knezevic A, Yang J, Shenvi N, Hinkes M, Roback JD, Easley KA, Josephson CD. Enteral iron supplementation, red blood cell transfusion, and risk of bronchopulmonary dysplasia in very-low-birth-weight infants. *Transfusion.* 2019 May;59(5):1675-1682. doi: 10.1111/trf.15216. Epub 2019 Feb 23. PubMed PMID: 30801736; PubMed Central PMCID: PMC6499698.
43. Gollub MJ, Blazic I, Bates DDB, Campbell N, Knezevic A, Gonen M, Lynn P, Weiser MR, Garcia-Aguilar J, Hötcker AM, Cercek A, Saltz L. Pelvic MRI after induction chemotherapy and before long-course chemoradiation therapy for rectal cancer: What are the imaging findings?. *Eur Radiol.* 2019 Apr;29(4):1733-1742. doi: 10.1007/s00330-018-5726-2. Epub 2018 Oct 2. PubMed PMID: 30280248; PubMed Central PMCID: PMC6420840.
44. Fortenberry JD, Nguyen T, Grunwell JR, Aneja RK, Wheeler D, Hall M, Fleming G, Tarrago R, Buttram S, Dalton H, Han Y, Easley KA, Knezevic A, Dai T, Paden M, Carcillo JA. Therapeutic Plasma Exchange in Children With Thrombocytopenia-Associated Multiple Organ Failure: The Thrombocytopenia-Associated Multiple Organ Failure Network Prospective Experience. *Crit Care Med.* 2019 Mar;47(3):e173-e181. doi: 10.1097/CCM.0000000000003559. PubMed PMID: 30531184; PubMed Central PMCID: PMC9084562.
45. Gollub MJ, Blazic I, Felder S, Knezevic A, Gonen M, Garcia-Aguilar J, Paty PP, Smith JJ. Value of adding dynamic contrast-enhanced MRI visual assessment to conventional MRI and clinical assessment in the diagnosis of complete tumour response to chemoradiotherapy for rectal cancer. *Eur Radiol.* 2019 Mar;29(3):1104-1113. doi: 10.1007/s00330-018-5719-1. Epub 2018 Sep 21. PubMed PMID: 30242504; PubMed Central PMCID: PMC6358522.
46. Horvat N, Raj A, Liu S, Matkowskyj KA, Knezevic A, Capanu M, Shia J, Pickhardt PJ, Gollub MJ. CT Colonography in Preoperative Staging of Colon Cancer: Evaluation of FOxTROT Inclusion Criteria for Neoadjuvant Therapy. *AJR Am J Roentgenol.* 2019 Jan;212(1):94-102. doi: 10.2214/AJR.18.19928. Epub 2018 Nov 13. PubMed PMID: 30422707; PubMed Central PMCID: PMC7959265.
47. Gollub MJ, Arya S, Beets-Tan RG, dePrisco G, Gonen M, Jhaveri K, Kassam Z, Kaur H, Kim D, Knezevic A, Korngold E, Lall C, Lalwani N, Blair Macdonald D, Moreno C, Nougaret S, Pickhardt P, Sheedy S, Harisinghani M. Use of magnetic resonance imaging in rectal cancer patients: Society of Abdominal Radiology (SAR) rectal cancer disease-focused panel (DFP) recommendations 2017. *Abdom Radiol (NY).* 2018 Nov;43(11):2893-2902. doi: 10.1007/s00261-018-1642-9. PubMed PMID: 29785540.

48. Carlo MI, Mukherjee S, Mandelker D, Vijai J, Kemel Y, Zhang L, Knezevic A, Patil S, Ceyhan-Birsoy O, Huang KC, Redzematovic A, Coskey DT, Stewart C, Pradhan N, Arnold AG, Hakimi AA, Chen YB, Coleman JA, Hyman DM, Ladanyi M, Cadoo KA, Walsh MF, Stadler ZK, Lee CH, Feldman DR, Voss MH, Robson M, Motzer RJ, Offit K. Prevalence of Germline Mutations in Cancer Susceptibility Genes in Patients With Advanced Renal Cell Carcinoma. *JAMA Oncol.* 2018 Sep 1;4(9):1228-1235. doi: 10.1001/jamaoncol.2018.1986. PubMed PMID: 29978187; PubMed Central PMCID: PMC6584283.
49. Laudati C, Clark C, Knezevic A, Zhang Z, Barton-Burke M. Hypersensitivity Reactions: Priming Practice Change to Reduce Incidence in First-Dose Rituximab Treatment. *Clin J Oncol Nurs.* 2018 Aug 1;22(4):407-414. doi: 10.1188/18.CJON.407-414. PubMed PMID: 30035788; PubMed Central PMCID: PMC6192040.
50. Akella SS, Francis JH, Knezevic A, Ostrovnaya I, Gobin YP, Friedman D, Guarini E, Eibeler L, Catalanotti F, Abramson DH. Growth patterns of survivors of retinoblastoma treated with ophthalmic artery chemosurgery. *PLoS One.* 2018;13(5):e0197052. doi: 10.1371/journal.pone.0197052. eCollection 2018. PubMed PMID: 29734385; PubMed Central PMCID: PMC5937785.
51. Titanji K, Vunnava A, Foster A, Sheth AN, Lennox JL, Knezevic A, Shenvi N, Easley KA, Ofotokun I, Weitzmann MN. T-cell receptor activator of nuclear factor- κ B ligand/osteoprotegerin imbalance is associated with HIV-induced bone loss in patients with higher CD4+ T-cell counts. *AIDS.* 2018 Apr 24;32(7):885-894. doi: 10.1097/QAD.0000000000001764. PubMed PMID: 29424771; PubMed Central PMCID: PMC5869175.
52. Hussen SA, Chakraborty R, Knezevic A, Camacho-Gonzalez A, Huang E, Stephenson R, Del Rio C. Transitioning young adults from paediatric to adult care and the HIV care continuum in Atlanta, Georgia, USA: a retrospective cohort study. *J Int AIDS Soc.* 2017 Sep 1;20(1):21848. doi: 10.7448/IAS.20.1.21848. PubMed PMID: 28872281; PubMed Central PMCID: PMC5705166.
53. Shah AD, Patel AU, Knezevic A, Hoskins MH, Hirsh DS, Merchant FM, El Chami MF, Delurgio DB, Patel AM, Leon AR, Langberg JJ, Lloyd MS. Clinical Performance of Magnetic Resonance Imaging Conditional and Nonconditional Cardiac Implantable Electronic Devices. *Pacing Clin Electrophysiol.* 2017 May;40(5):467-475. doi: 10.1111/pace.13060. Epub 2017 Apr 5. PubMed PMID: 28224629.
54. Ofotokun I, Titanji K, Lahiri CD, Vunnava A, Foster A, Sanford SE, Sheth AN, Lennox JL, Knezevic A, Ward L, Easley KA, Powers P, Weitzmann MN. A Single-dose Zoledronic Acid Infusion Prevents Antiretroviral Therapy-induced Bone Loss in Treatment-naïve HIV-infected Patients: A Phase IIb Trial. *Clin Infect Dis.* 2016 Sep 1;63(5):663-671. doi: 10.1093/cid/ciw331. Epub 2016 May 18. PubMed PMID: 27193748; PubMed Central PMCID: PMC4981757.
55. Delaney M, Mayock D, Knezevic A, Norby-Slycord C, Kleine E, Patel R, Easley K, Josephson C. Postnatal cytomegalovirus infection: a pilot comparative effectiveness study of transfusion safety using leukoreduced-only transfusion strategy. *Transfusion.* 2016 Aug;56(8):1945-50. doi: 10.1111/trf.13605. Epub 2016 Apr 15. PubMed PMID: 27080192; PubMed Central PMCID: PMC5874797.
56. Merchant FM, Hoskins MH, Benser ME, Roberts G, Bastek AN, Knezevic A, Huang Y, Langberg JJ, Leon AR, El-Chami MF. Time Course of Subsequent Shocks After Initial Implantable Cardioverter-Defibrillator Discharge and Implications for Driving Restrictions. *JAMA Cardiol.* 2016 May 1;1(2):181-8. doi: 10.1001/jamacardio.2015.0386. PubMed PMID: 27437889.
57. Patel RM, Knezevic A, Shenvi N, Hinkes M, Keene S, Roback JD, Easley KA, Josephson CD. Association of Red Blood Cell Transfusion, Anemia, and Necrotizing Enterocolitis in Very Low-Birth-Weight Infants. *JAMA.* 2016 Mar 1;315(9):889-97. doi: 10.1001/jama.2016.1204. PubMed PMID: 26934258; PubMed Central PMCID: PMC4805423.

58. Titanji K, Vunnava A, Sheth AN, Delille C, Lennox JL, Sanford SE, Foster A, Knezevic A, Easley KA, Weitzmann MN, Ofotokun I. Dysregulated B cell expression of RANKL and OPG correlates with loss of bone mineral density in HIV infection. *PLoS Pathog.* 2014 Oct;10(10):e1004497. doi: 10.1371/journal.ppat.1004497. eCollection 2014 Oct. PubMed PMID: 25393853; PubMed Central PMCID: PMC4231117.
59. Josephson CD, Caliendo AM, Easley KA, Knezevic A, Shenvi N, Hinkes MT, Patel RM, Hillyer CD, Roback JD. Blood transfusion and breast milk transmission of cytomegalovirus in very low-birth-weight infants: a prospective cohort study. *JAMA Pediatr.* 2014 Nov;168(11):1054-62. doi: 10.1001/jamapediatrics.2014.1360. PubMed PMID: 25243446; PubMed Central PMCID: PMC4392178.
60. Guzzetta NA, Monitz HG, Fernandez JD, Fazlollah TM, Knezevic A, Miller BE. Correlations between activated clotting time values and heparin concentration measurements in young infants undergoing cardiopulmonary bypass. *Anesth Analg.* 2010 Jul;111(1):173-9. doi: 10.1213/ANE.0b013e3181e13470. Epub 2010 Jun 2. PubMed PMID: 20519414.

BOOK CHAPTERS

1. Panageas KS, Knezevic A. Selection of endpoints. In: Halabi S, Michiels S, editors. *Textbook of Clinical Trials in Oncology*. CRC Press, 9-26.

CONFERENCE PAPERS

1. Knezevic A, Patil S. (2020). "Combination weighted log-rank tests for survival analysis with non-proportional hazards." SAS Global Forum, 2020 Mar 29-Apr 1.